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 2011 National Lung Screening Trial demonstrates 
reduced morbidity and mortality with LDCT 
compared to CXR. 
 2013 USPSTF lung cancer screening guidelines 
updated.
 2015 <5% of eligible patients undergo lung cancer 
screening.
Next Step: Bronchoscopy
Mediastinal Tumors
Tracheomalacia
CT shows thickening of trachea and bronchi.
Amyloid Subtypes
Discussion
Take Home Points
Lung Cancer Screening:
 One lung cancer death prevented for every 320 
average risk patients screened with CT (vs CXR).
 20% of patients will have false positive findings 
requiring further evaluation. 
Amyloidosis:
 Amyloid in the tissue requires testing for subtype & 
systemic disease. 
 The AL amyloid subtype is associated with plasma 
cell dyscrasias. 
 Localized tracheobronchial amyloidosis is one of 
three types of pulmonary amyloidosis.
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70 year old female with PMHX of COPD who suffers 
from chronic dyspnea with exertion, and cough.
The patient has a 54 pack year smoking history, and 
quit smoking 2 years ago. In accordance with the 
USPSTF guideline, she was referred for lung cancer 
screening.
Medical History:
Diabetes
GERD
Fibromyalgia
Uterine Cancer
CKD, Stage II
Medications:
Albuterol
Fluticasone-
Salmeterol
Simvastatin
Ranitidine
Metformin 
Amitriptyline
Vit D/Calcium
Labs:
CBC: WNL
Electrolytes: WNL
Ca: 9.5
Cr : 0.9
Background
Lung Cancer Screening
DDX: Central Airway Obstruction
Amyloid in the LungIncidental Central Airway Thickening Found on CTIntroduction
Tracheobronchial amyloidosis:
Deposits in trachea and bronchi. 
Usually localized. 
AL subtype is most common.
Treated symptomatically. 
Nodular Pulmonary 
Amyloidosis:
Nodular deposits. Localized. 
Associated with systemic B-cell 
neoplasm, & Sjogren’s. 
Good prognosis. 
Diffuse Alveolar-Septal 
Amyloidosis:
Deposits in septa and vessel 
walls. AL or ATTRwt subtypes are 
most common. Systemic. 
Often asymptomatic.
This case explores one patient’s lung cancer screening, 
and the >$5,000 work up that followed. 
 Lung cancer screening can save lives but often with 
a cost. Physicians must educate patients about the 
risk of false positive results necessitating additional 
testing.
 To make a final diagnosis in this patient more testing 
was required with: bronchoscopy, pathology, mass 
spectrometry, SPEP, UPEP, serum free light chains, 
and a fat pad biopsy. 
 Her final diagnosis, localized tracheobronchial 
amyloidosis, is managed symptomatically with 
surgical treatments and stenting.
Bronchoscopy image. Pathology: Congo red stain & polarized light.
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Plasma cell dyscrasias
(MGUS, multiple 
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Rheumatoid arthritis, 
inflammatory bowel 
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Age
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USPSTF Guideline: Recommends “screening for lung 
cancer with low-dose computed tomography (LDCT) in 
adults aged 55 to 80 years who have a 30 pack-year 
smoking history and currently smoke or have quit within 
the past 15 years. Screening should be discontinued 
once a person has not smoked for 15 years or develops 
a health problem that substantially limits life expectancy 
or the ability or willingness to have curative lung 
surgery.”
Benefits:
 Higher cure rates. 
 Less invasive resection.
 Decreased rates of 
smoking. 
Harms
 False positive and 
incidental findings.
 Further work-up: cost, 
stress.
 Radiation exposure
 Overdiagnosis.
National Lung Cancer 
Screening Trial (NLST):
CXR vs. low radiation chest 
CT for lung cancer 
screening.
 Number needed to screen 
to prevent one lung cancer 
related death: 320
 20% reduction in relative 
lung cancer mortality.
 24% of LDCTs were 
abnormal. 96% of those, 
had false positive findings 
with 90% requiring further 
investigation. 
